Incidence and Outcome of BCR‐ABL Mutated Chronic Myeloid Leukemia Patients Who Failed to Tyrosine Kinase Inhibitors

Cancer Medicine- United Kingdom

doi 10.1002/cam4.2410

Related search

Who 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors

Turkish Journal of Haematology

English

Tyrosine Kinase Inhibitors in BCR-ABL Positive Acute Lymphoblastic Leukemia

English

Current Status of ABL Tyrosine Kinase Inhibitors Stop Studies for Chronic Myeloid Leukemia

Stem Cell Investigation

English

Differential Genomics and Transcriptomics Between Tyrosine Kinase Inhibitor-Sensitive and -Resistant BCR-ABL-dependent Chronic Myeloid Leukemia

English

BCR-ABL Tyrosine Kinase

Science-Business eXchange

English

Management of Chronic Myeloid Leukemia With BCR/ABL Inhibitors: Current Status and Future Perspectives

Clinical Medicine Insights: Therapeutics

Pharmaceutical Science

English

Combined Inhibition of MDM2 and BCR-Abl Tyrosine Kinase Targets Chronic Myeloid Leukemia Stem/Progenitor Cells in a Murine Model

English

Complications of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia - Chronic Phase

Revista de Chimie

Materials Science

Materials Chemistry

English

Future Perspectives of Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia

Chemotherapy: Open Access

English